管理式医疗人群中系统性治疗银屑病患者恶性肿瘤发生率的大型队列研究
该研究纳入1998至2011年Kaiser Permanente Northern California健康计划中5889例接受至少一种系统性抗银屑病药物治疗的成人银屑病患者。整体癌症发生率在生物制剂暴露组与非生物制剂组相当(aHR 0.86,95%CI 0.66-1.13),但生物制剂暴露组NMSC发生率升高42%(aHR 1.42,95%CI 1.12-1.80),主要由皮肤鳞状细胞癌风险增加驱动(aHR 1.81,95%CI 1.23-2.67)。
要点
- 生物制剂暴露未增加整体癌症风险(aHR 0.86)。
- 生物制剂暴露者NMSC风险升高42%(aHR 1.42)。
- 皮肤鳞状细胞癌风险增加最明显(aHR 1.81)。
核心结论
- 系统性治疗银屑病患者中,曾暴露于生物制剂者皮肤鳞状细胞癌发生率增加,多数生物制剂为TNF-α抑制剂。
研究设计与样本
- 回顾性队列研究,纳入5889例1998至2011年诊断为银屑病并接受至少1种系统性抗银屑病药物治疗的成人健康计划成员。
主要发现
- 整体癌症发生率在曾用生物制剂者与未用生物制剂者间相当(aHR 0.86,95%CI 0.66-1.13)。
- NMSC发生率在曾暴露于生物制剂者中高42%(aHR 1.42,95%CI 1.12-1.80)。
- 皮肤鳞状细胞癌风险增加(aHR 1.81,95%CI 1.23-2.67)。
- 大多数生物制剂暴露成员使用TNF-α抑制剂(n=2214,97%)。
临床怎么用
- 对曾暴露于生物制剂的系统性治疗银屑病患者,可考虑加强皮肤癌监测。
局限性
- 缺乏疾病严重程度信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moderate to severe psoriasis often requires treatment with systemic agents, many of which have immunosuppressive properties and could increase cancer risk, including nonmelanoma skin cancer (NMSC). OBJECTIVE: We sought to estimate the overall malignancy rate (excluding NMSC) and NMSC rate among 5889 patients with systemically treated psoriasis. METHODS: We identified a cohort of adult Kaiser Permanente Northern California health plan members with psoriasis diagnosed from 1998 to 2011 and treated with at least 1 systemic antipsoriatic agent and categorized them into ever-biologic or nonbiologic users. Malignancy rates were calculated per 1000 person-years of follow-up with 95% confidence intervals (CI). Crude and confounder-adjusted hazard ratios (aHRs) were calculated using Cox regression. RESULTS: Most biologic-exposed members were treated with TNF-alfa inhibitors (n = 2214, 97%). Overall incident cancer rates were comparable between ever-biologic as compared to nonbiologic users (aHR 0.86, 95% CI 0.66-1.13). NMSC rates were 42% higher among individuals ever exposed to a biologic (aHR 1.42, 95% CI 1.12-1.80), largely driven by increased cutaneous squamous cell carcinoma risk (aHR 1.81, 95% CI 1.23-2.67). LIMITATIONS: No information was available on disease severity. CONCLUSION: We found increased incidence of cutaneous squamous cell carcinoma among patients with systemically treated psoriasis who were ever exposed to biologics, the majority of which were TNF-alfa inhibitors. Increased skin cancer surveillance in this population may be warranted.
引用
- Asgari MM, Ray GT, Geier JL, et al. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017. PMID: 28162854. doi:10.1016/j.jaad.2016.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。